Search for: "Lilly v. Heard"
Results 101 - 120
of 149
Sorted by Relevance
|
Sort by Date
3 Jun 2010, 1:37 pm
Eli Lilly & Co., 854 N.E.2d 372 (Ind. [read post]
25 May 2015, 1:28 am
In Human Genome Sciences Inc. v Eli Lilly and Company [2011] UKSC 51 the Supreme Court reversed the findings of the High Court and Court of Appeal. [read post]
18 Nov 2011, 6:51 am
The IPKat heard about this from a number of sources which included, via the social media, the IPO itself. [read post]
11 Aug 2010, 1:15 am
and industrial applicability in Eli Lilly & Co v Human Genome Sciences Inc, noted by the IPKat here, is (according to a normally reliable source whom the Kat thanks) to be heard by the Supreme Court on Thursday 7 October. [read post]
15 Nov 2013, 11:34 am
Eli Lilly & Co. v. [read post]
13 Apr 2019, 12:25 pm
| Applying the Actavis questions to numerical limitations: Regen Lab v Estar | Formstein defence in the UK? [read post]
Discovery Rule, Cross-Jurisdictional Tolling, and "Equitable" Tolling Cannot Save Aredia-Zometa Case
16 Oct 2013, 4:30 am
In Jolly v. [read post]
28 Jun 2013, 5:02 am
The court in Saavedra v. [read post]
10 Jun 2014, 7:44 pm
In this post, guest contributor Paul England (Taylor Wessing LLP) explains the legal issues and their consequences:UKIPO -- a 'court' for the purposes of the Brussels I Regulation Some courts look like this ...With Actavis v Eli Lilly [noted on the IPKat here] still fresh in our minds, and amendments to the Brussels I Regulation (recast) progressing through the European Parliament in preparation for the Unified Patent Court, jurisdictional matters are a hot… [read post]
29 Nov 2006, 11:41 am
On Monday, the Supreme Court heard argument in Ledbetter v. [read post]
10 Mar 2010, 12:30 pm
Let’s start with Bloate v. [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP Watch) Is the practice of medicine… [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP Watch) Is the practice of medicine… [read post]
21 Jan 2007, 5:42 pm
I have heard some of these concerns in the past few years, especially in the wake of the eBay injunction case. [read post]
31 Aug 2012, 9:00 am
ROBERT V. [read post]
4 May 2016, 9:26 am
Eli Lilly & Co., 1998 WL 35152135, **3-4 (D. [read post]
29 Jan 2021, 7:20 am
If that turns out to the case then Illumina Cambridge Limited v Latvia MGI Tech SIA and others is a substantial judgment to mark this departure. [read post]
28 Apr 2024, 11:33 am
To give the reader some idea of the artificial flavor of Egilman’s pomposity, paragraph 8 of his remarkable declaration avers” “My views on the scientific standards for the determination of cause-effect relationships (medical epistemology) have been cited by the Massachusetts Supreme Court (Vassallo v. [read post]
1 Feb 2013, 9:42 am
Maybe you’ve heard of it. [read post]
28 May 2012, 4:17 am
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
